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Abstract
Background—Merkel cell carcinoma (MCC) is an aggressive cutaneous malignancy, but little is
known about the presence or characteristics of MCC in mainland China. A retrospective chart
review was conducted to describe the clinical profile of Merkel cell carcinoma in China.
Methods—At 18 cancer or dermatology hospitals in metropolitan centers from the six
geographical regions of mainland China, approximately 3,100,000 pathology database and
medical records were searched for cases that had a pathological diagnosis of MCC between 1970
and 2009. A case series was compiled from retrospective chart reviews of identified MCC
patients.
Results—Eight out of 18 participating hospitals reported at least one record of a patient with a
pathological diagnosis of MCC, and a total of 22 cases were identified. The median age of patients
was 65.5, and 59% were female. The median time from the appearance of a lesion to the time of
biopsy was 6 months, and the most common location of lesions was the head and neck. The most
common treatment used was surgery alone.
Conclusions—MCC appears to be uncommon in mainland China. Patients in this series are
elderly, often had lesions on the head/neck region, and most commonly received surgery alone as
treatment. In contrast with MCC in Western countries, the current series' patients were all of Asian
ethnicity, had larger lesions at presentation, and none were documented as having HIV or other
forms of immunosuppression.
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Merkel cell carcinoma (MCC) is a cutaneous malignancy thought to arise from the Merkel
cell mechanoreceptors located in the epidermis, and it has a clinical mortality (33%) about
twice that of melanoma (15%).1 Reports from the United States have described a tripling in
the incidence of MCC from 1986 to 2001,2, 3 with a current estimated incidence of 1,500
cases/year.4 In 2008, the Merkel cell polyomavirus (MCPyV) was found to be associated
with MCC tumors,5 and evidence is growing that links the MCPyV with oncogenesis of
MCC.6, 7 The epidemiology and clinical characteristics of MCC have been studied in
Europe, Australia, and North America,8–10 but have not yet been examined in China aside
from a few case reports.11, 12
Little is known about the presence or characteristics of MCC in China, and there is no
existing cancer registry or similar resource which has collected information on MCC. While
MCC is a rare cutaneous malignancy which predominantly affects elderly Caucasians, it is a
challenging and aggressive disease with high mortality (as high as 1 in 3) and is associated
with immunosuppression.1, 13 In order to evaluate the presence and characteristics of MCC
in China, we conducted a national medical chart-review to describe the clinical profile and
manifestations of MCC in mainland China.
Methods
A national retrospective chart review was conducted at 18 participating hospitals
representing each of the six main geographical regions of mainland China (East, Mid-South,
North, Northeast, Northwest, and Southwest (Figure 1)). Physicians at the pathology
departments at the central “tumor” or cancer hospitals in the main provinces and
municipalities of these regions were contacted, in addition to dedicated dermatological
hospitals if available. As this study focused on mainland China, institutions in Hong Kong,
Macao, and Taiwan were not included.
Participating physicians consulted their existing hospital electronic medical records and
pathology records for cases of Merkel cell carcinoma (ICD-10 ID C44, pathology
morphology code 8247/3)14 identified from 1970 to 2009. A total of approximately
3,100,000 medical records was searched for cases with a pathological diagnosis of MCC,
including both primary diagnoses and referrals. A Chinese-language questionnaire was used
to collect clinical information based on previous literature regarding salient features of
MCC,1, 13, 15 including patient demographics and clinico-pathological information regarding
the characteristics of the skin lesion, pathological findings, concurrent diseases, and
treatment. If cases existed, the corresponding charts were reviewed and the questionnaires
were returned to the research group at the Cancer Institute, Chinese Academy of Medical
Sciences for analysis. No contact with human subjects or analyses of stored biological
specimens was conducted. This study was approved by the Public Health-Nursing
institutional review board at the University of North Carolina, Chapel Hill, and by a central
institutional review board at the Cancer Institute, Chinese Academy of Medical Sciences.
Results
Eight out of 18 participating institutions reported at least one case of MCC, and a total of 22
cases were identified (Table 1). One case was diagnosed in 1996, while the remaining 21
cases were diagnosed in 2001 or after. Participating institutions covered all 6 geographical
regions of mainland China, including 14 cities in 13 provinces or metropolitan regions. The
institution with the highest number of cases (n=8) was the Cancer Institute, Chinese
Academy of Medical Sciences in Beijing.
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Of the 22 MCC cases identified, nine (41%) were male, while 13 (59%) were female (Table
2). The median age of the patients was 65.5 years old (range 21–79, average 59). Twenty-
one of 22 patients (95%) were of the Han Chinese ethnic majority, while one was of Hui
minority background.
The median time from the appearance of a lesion to the time a biopsy was taken was 6
months (range 1–39, average 8.5). The most common location of lesions was the head and
neck (9 cases, 41%), followed by the lower limb (5 cases, 23%), lymph nodes (3 cases,
14%), upper limb (2 cases, 19%) groin/buttock (2 cases, 19%), and torso (1 case, 5%). The
maximum diameter at time of presentation of most lesions, whether cutaneous or lymph
nodal, was greater than 2cm (15 cases, 71%), followed by lesions between 1 and 2cm (4
cases, 19%) and lesions smaller than 1cm (2 cases, 10%). Data on the color of lesions was
available for 17 cases, and the most common colors were pink (5 cases, 30%), skin or flesh-
color (5 cases, 30%), followed by white/gray (3), yellow/white (2), bluish-purple (1), and
pinkish-red (1).
Six patients (27%) presented with lymphadenopathy at the time of diagnosis, two (9%) with
metastatic disease, and two (9%) with both lymphadenopathy and metastatic disease. No
patients were recorded as being HIV sero-positive, having chronic lymphocytic leukemia, or
taking immunosuppressive medications for a pre-existing condition. The most common
clinical diagnosis before pathology results was skin cancer (15 cases, 71%), followed by a
cyst (4 cases, 19%). Two cases (10%) were thought to be MCC, while infections (2 cases),
other cancers (3 cases), and acne (1 case) were also considered.
CK20 staining on immunohistochemistry was reported in 13 patients (59%); nine of these
patients (69%) had a positive result while four (31%) had a negative result. The most
common treatment used was surgery alone (10 cases, 45%), followed by surgery and
radiation (5 cases, 23%), surgery and chemotherapy (4 cases, 18%), and surgery, radiation,
and chemotherapy (3 cases, 14%).
Follow-up information on the status of patients following initial diagnosis or hospital
admission was available for 13 patients. Of these, six (46%) had recurrent disease detected
at a median of 6 months; five (38%) were alive with no record of recurrence at a median of 3
months; and two (15%) were dead after a median of 28 months.
Comment
This study presents a basic clinical profile of 22 patients with MCC identified in the medical
records of 18 cancer or dermatology hospitals in mainland China. This series provides an
initial step towards describing MCC in China and ascertaining whether MCC in China has
similar clinical characteristics to Western MCC cases. Based on our reports from pathology
laboratories across China, MCC appears to be uncommon but still occurs in diverse regions
of China. This infrequency is not surprising, given that MCC in Western countries typically
occurs in Caucasian patients at low incidence rates of 0.44 cases per 100,000.2, 3 In our
series, most cases were diagnosed in 2001 or later, likely due to the fact that while an
electronic search of existing records was conducted, some of the participating institutions
did not yet have complete digitalized records extending to the 1990's or earlier.
All of the patients in our series were of Asian descent (all were Han Chinese, while one was
of the Hui ethnic minority), while published series on MCC have largely reported on
Caucasians.10, 13, 16, 17 In a recent study on 3,870 MCC cases from the United States, only
4.1% of cases were among Asians (but also including American Indians and Asian Pacific
Islanders).10
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Given that sun exposure is a known risk factor for MCC,1 increased sun exposure may also
be a risk factor for these Asian patients. At least 12 of the 22 patients in this Chinese series
had their primary lesions located on highly or moderately sun-exposed areas such as the
head and neck or the hand. While these results are not conclusive, MCC appears to be more
common on sun-exposed anatomical areas as in Caucasian populations.1, 10
While MCC is typically more common in men,2, 3, 10 this series had a majority of women
(59%). This may be due to the relatively small sample size of MCC cases ascertained, or the
possibility that women were more likely than men to seek dermatological consultation in
China. The age at diagnosis in our series (median 65.5) is in agreement with findings that
MCC is associated with older age above 65 years old among Caucasian
populations.2, 3, 10, 17
The median and mean duration from appearance of a lesions to the time of biopsy in this
study (6 and 8.5 months, respectively) are relatively longer than those previously reported in
a study of 195 patients from the United States (3 and 5.3 months, respectively).13 This
longer duration before clinical presentation may be one of the reasons why most MCC
lesions in this series were larger (71% were >2 cm in diameter) than the lesions encountered
in the U.S., where most lesions are between 1–2 cm at presentation.13, 15 The most common
colors of lesions in this series were pink or red, and flesh/skin-colored. Compared with a
previous study of 195 MCC patients from the U.S., there was a lower frequency of blue/
purple lesions but a larger frequency of lesions with a white color (either white/gray or
white/yellow).13 While additional data are needed, we speculate that these differences may
have to do with the appearance of these lesions on Asian skin versus Caucasian skin.
Approximately half (45%) of the patients had either lymphadenopathy, metastatic disease, or
both at presentation, being similar with previous studies which found that ~ 30–43% of
patients presented with metastatic or nodal disease.13, 15 While a U.S. study found that
initial clinical diagnoses of primary MCC lesions at the time of biopsy were predominantly
non-melanoma skin cancer (19%) or cyst/acneiform lesions (32%),13 skin cancer was more
often considered as the initial diagnosis (71%) in our series, along with a few alternative
diagnoses considered such as sporotrichosis or cysts.
All patients in this series from China received surgical treatment, while approximately a
third received additional radiation or chemotherapy, and 3 (14%) received all three treatment
modalities. In contrast, a study of 251 patients in the U.S. reported that almost all patients
received surgery for primary lesions, while 17% received radiation, and 12% received
chemotherapy depending on the extent of disease.15 Despite the rarity of MCC and the lack
of national guidelines for treating MCC, surgery is the main treatment modality employed
thus far in China. There did not appear to be an association between the mode of treatments
and the presence of nodal or metastatic disease at presentation in this Chinese series.
Follow-up survival data, while only available in 13 cases, suggest a similarly aggressive
disease course in China as in other countries, with 39% of patients alive with no record of
recurrence at latest follow-up and 61% experiencing recurrent disease or death. This relapse
rate of 61% appears to be high compared to rates in other series of MCC cases from the
United States of 43%.15 Although our sample size of cases with recurrence is small, possible
reasons for these observed differences in relapse rates include the larger primary tumor sizes
at presentation, longer latency times between appearance of the lesion to the time of clinical
presentation, and the high rates of lymphadenopathy or metastasis at time of diagnosis
among MCC cases in our series. Additionally, the general absence of standardized clinical
treatment guidelines and low rates of adjuvant radio- or chemotherapy in China may have
contributed to the relatively higher relapse rate. Patients in our series who were alive only
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had a median of 3 months of follow-up, and other studies have found that most recurrences
occur within 2 years and most deaths within 3 years.15 One limitation of our study is that
complete follow-up data were unavailable for some MCC patients, as no system for active
follow-up is yet available in China for this rare disease. Thus, some of the patients who did
not have follow-up may have died after their latest clinical encounter. In China, this may be
due to a lack of clinical experience with a rare condition like MCC, or due to limited
healthcare resources or access.
This case series has several other important limitations. Although included MCC cases were
from diverse geographical areas, the participating institutions were urban tertiary care
centers which do not necessarily constitute a representative sample of the Chinese
population. Further, not all MCC cases in this chart review had complete clinical data, and
the study did not include a secondary review of pathology slides to confirm MCC diagnoses,
or radiographic and laboratory exclusion of small-cell lung cancer. The rarity of MCC and
the lack of uniform use of techniques such as CK-20 immunohistochemistry staining may
have led to either over- or under-diagnosis at these centers.18 However, the inclusion of
several hospitals from each of the main six regions of China provided a somewhat broad
geographical sample, and the use of large tertiary cancer institutions in this series allowed us
to obtain reliable chart review data.
To date, very little has been reported about the presence or characteristics of MCC in
mainland China. We speculate that even though MCC most commonly occurs among
Caucasians, China's extremely large population may have many other undiagnosed or
untreated cases of MCC affecting people from rural and remote regions, or in local
community hospitals. There may also be interesting treatment-seeking behaviors or
treatment options, including traditional Chinese medicine, that are being used to treat MCC
or other cutaneous malignancies. Currently, China's National Cancer Registry does not
collect data on MCC, and there are no national guidelines for MCC diagnosis and treatment.
Thus, further studies are needed to investigate the epidemiology, diagnosis, and treatment of
MCC in China.
This case series has findings consistent with the published literature on MCC, such as the
elderly age of patients, the common location of lesions on the head/neck region, and the use
of surgery as the primary treatment method. There are, however, several interesting
differences in this case series from China, such as that these patients are all of Asian
ethnicity, while most previous studies on MCC report on Caucasian patients in Western
countries. MCC in East Asia has been reported in single-hospital based case series on 7
patients from South Korea19 and 16 MCC patients from Japan,20 both of which similarly
found that MCC predominates on the head/neck region in the elderly, and is treated
primarily with surgery. None of the patients in our series were documented as having HIV,
chronic lymphocytic leukemia, or taking immunosuppressive medications. It is still possible,
however, that these conditions may play a role in MCC in China as in the West.1 Further
studies are warranted to investigate the role of immunosuppression, as well as the role of the
Merkel cell polyomavirus, in the development of MCC in Chinese patients.
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Map showing the six geographical regions of mainland China. Blue stars indicate the
location of participating hospitals.
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Table 2
Summary of Selected Clinical Characteristics of Patients with Merkel Cell Carcinoma in Mainland China
Number Percent, other
Sex (n=22)
 Male 9 41
 Female 13 59
Age (years) (n=22) Median 65.5, mean 59, range 21–79
Time from appearance of lesion to biopsy (months) Median 6, mean 8.5, range 1–39
Lesion Location at Presentation (n=22)
 Head/neck 9 41
 Lower limb 5 23
 Upper limb 2 19
 Lymph nodes 3 14
 Groin/Buttock 2 9
 Torso 1 5
Size of Lesion (n=20)
 <1cm 2 10
 1–2cm 4 19
 >2cm 15 71
Color of Lesion (n=17)
 Pink 5 30
 Skin/flesh-colored 5 30
 White/Gray 3 18
 Yellow/White 2 12
 Pink/red 1 10
 Bluish/purple 1 6
Conditions present at diagnosis (n=8, 45% of total)
 Lymphadenopathy (LAD) 6 27
 Metastatic disease 2 9
 LAD and metastatic disease 2 9
Treatment Received (n=22)
 Surgery 10 45
 Surgery, Radiation 5 23
 Surgery, Chemotherapy 4 18
 Surgery, Radiation, Chemotherapy 3 14
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